Drug Profile
JNJ 440
Alternative Names: ALS-003440; JNJ-0440; JNJ-64530440; JNJ440Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Alios BioPharma
- Class Antivirals; Hepatoprotectants
- Mechanism of Action Capsid protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers) in Japan (PO, Tablet)
- 28 Jan 2022 No recent reports of development identified for preclinical development in Hepatitis-B in New Zealand (PO, Liquid)
- 28 Apr 2021 No recent reports of development identified for phase-I development in Hepatitis-B in Moldova (PO, Tablet)